July 11, 2017
Jurors in the Martin Shkreli securities fraud trial Tuesday heard of how one of his hedge funds had negative 33 cents to its name in summer 2011, around the same time Shkreli was claiming the fund had tens of millions of dollars in assets under management.
July 10, 2017
One of the investors describing his struggle to get his money out of the hedge fund Martin Shkreli shuttered to run his new company Retrophin Inc. told the federal jury at Shkreli's Brooklyn fraud trial Monday that the ex-pharma executive's intense focus reminded him of the title character in the movie "Rain Man."
July 07, 2017
A former analyst for Martin Shkreli's hedge funds and then-nascent drug company Retrophin called the controversial former pharmaceutical executive "a scam artist," jurors heard Friday, while the companies' former chief operating officer testified about secretly reporting them to the Securities and Exchange Commission.
July 06, 2017
A former analyst for Martin Shkreli's MSMB Capital Management on Thursday told a Brooklyn federal jury about the aftermath of his botched short of Orexigen Therapeutics stock that wrecked the hedge fund, saying Shkreli was left "depressed in a way I had not seen him before."
July 05, 2017
A New York federal judge on Wednesday ordered controversial former pharmaceutical company CEO Martin Shkreli to keep his mouth shut around the courthouse where he's standing trial on securities fraud charges, after Shkreli walked into a room of reporters last week and ripped prosecutors and a government witness.
June 30, 2017
An investor in a short-lived, health care-focused hedge fund run by Martin Shkreli on Friday testified that he lost his entire $4.8 million stake in the fund after Shkreli couldn't make a margin call by Lehman Brothers, which sued for the funds it lost from the former pharma entrepreneur's trading.
June 29, 2017
A former investor in one of Martin Shkreli's hedge funds on Thursday testified on how she felt "betrayed" by the now former Retrophin Inc. boss after being informed that her money had been used to prop up his fledgling drug company, in spite of his promise to cash out her position.
June 28, 2017
An attorney for Martin Shkreli told a Brooklyn federal jury Wednesday that the former Retrophin Inc. CEO is an eccentric genius who never defrauded his investors or deceived the company's board members, as the long-awaited trial of the controversial "pharma bro" kicked off.
June 27, 2017
Jury selection dragged on for a second day in the securities fraud trial of former pharmaceutical executive Martin Shkreli without any jurors making it to the final panel, while Shkreli's lead attorney moved for a mistrial, saying on Tuesday that a barrage of negative press coverage left the jury selection process "irreparably tainted."
June 26, 2017
Jury selection began on Monday in the securities fraud trial of former Retrophin Inc. and Turing Pharmaceuticals boss Martin Shkreli, with roughly 20 potential jurors being excused for cause due to their opinions of the controversial pharma executive, who one juror called, "the most hated man in America."